Table of Content

1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP-DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. SUPPORTIVE GOVERNMENT POLICIES IN US AND CANADA
3.2.2. DEMAND FOR NEWBORN SCREENING INSTRUMENTS IS RISING STEADILY
3.2.3. GROWTH IN DRY BLOOD SPOT TEST
3.2.4. TECHNIQUES USED IN NEWBORN SCREENING TESTS

4. MARKET DYNAMICS
4.1. ETYMOLOGY OF NEWBORN SCREENING
4.2. MARKET SCOPE & DEFINITION
4.3. MARKET DRIVERS
4.3.1. INCREASE IN OCCURRENCES OF NEWBORN DISEASES
4.3.2. GROWING NUMBER OF INFANTS WITH BIRTH DEFECT
4.3.3. BACKING OF GOVERNMENT TOWARDS NEWBORN CHILD HEALTH
4.3.4. RISING AWARENESS FOR PEDIATRIC CONGENITAL HEART DISEASE
4.4. MARKET RESTRAINTS
4.4.1. ABSENCE OF PROPER HEALTHCARE INFRASTRUCTURE FOR NEWBORN BABIES IN DEVELOPING COUNTRIES
4.4.2. SOCIO-ECONOMIC HURDLES IN THE IMPLEMENTATION OF NEWBORN CHILD SCREENING
4.5. MARKET OPPORTUNITIES
4.5.1. INCREASING FERTILITY RATES ACROSS THE GLOBE IS CREATING DYNAMIC GROWTH
4.5.2. NEWBORN SCREENING HELPS IN EARLY IDENTIFICATION AND MANAGEMENT OF AFFECTED NEWBORNS
4.5.3. TECHNOLOGICAL ADVANCEMENTS IN NEWBORN SCREENING
4.5.4. INCREASE IN NUMBER OF PREGNANT WOMEN WITH ADVANCED MATERNAL AGE
4.6. MARKET CHALLENGES
4.6.1. DEARTH OF SKILLED PROFESSIONAL IN HEALTHCARE INDUSTRY
4.6.2. MAINTENANCE OF EQUIPMENT IN HOSPITAL

5. MARKET BY PRODUCT
5.1. NEWBORN SCREENING INSTRUMENTS
5.2. NEWBORN SCREENING REAGENTS & ASSAY KITS

6. MARKET BY TEST TYPE
6.1. HEARING SCREEN TEST
6.2. CRITICAL CONGENITAL HEART DISEASE (CCHD) TEST
6.3. DRY BLOOD SPOT TEST

7. MARKET BY TECHNOLOGY
7.1. TANDEM MASS SPECTROMETRY
7.2. PULSE OXIMETRY
7.3. ENZYME BASED ASSAYS
7.4. DNA BASED ASSAYS
7.5. ELECTROPHORESIS
7.6. OTHERS

8. KEY ANALYTICS
8.1. PORTER’S FIVE FORCE MODEL
8.1.1. THREAT OF NEW ENTRANTS
8.1.2. THREAT OF SUBSTITUTE
8.1.3. BARGAINING POWER OF SUPPLIERS
8.1.4. BARGAINING POWER OF BUYERS
8.1.5. THREAT OF COMPETITIVE RIVALRY
8.2. KEY BUYING CRITERIA
8.2.1. RELIABILITY
8.2.2. COST
8.2.3. AVAILABILITY
8.2.4. TECHNOLOGICAL ADVANCEMENT
8.3. OPPORTUNITY MATRIX
8.4. VENDOR LANDSCAPE
8.5. VALUE CHAIN ANALYSIS
8.5.1. RAW MATERIAL SUPPLIERS
8.5.2. MANUFACTURERS
8.5.3. DISTRIBUTORS
8.5.4. END-USERS
8.6. LEGAL, POLICY & REGULATORY FRAMEWORK

9. NORTH AMERICA
9.1. UNITED STATES
9.2. CANADA

10. COMPETITIVE LANDSCAPE
10.1. MARKET SHARE ANALYSIS
10.2. CORPORATE STRATEGIES
10.2.1. PRODUCT LAUNCH
10.3. COMPANY PROFILES
10.3.1. SCIEX
10.3.1.1. OVERVIEW
10.3.1.2. PRODUCT PORTFOLIO
10.3.1.3. STRATEGIC INITIATIVES
10.3.1.4. SCOT ANALYSIS
10.3.2. BIOTEK INSTRUMENTS INC.
10.3.2.1. OVERVIEW
10.3.2.2. PRODUCT PORTFOLIO
10.3.2.3. STRATEGIC INITIATIVES
10.3.2.4. SCOT ANALYSIS
10.3.3. BIO-RAD LABORATORIES INC.
10.3.3.1. OVERVIEW
10.3.3.2. PRODUCT PORTFOLIO
10.3.3.3. STRATEGIC INITIATIVES
10.3.3.4. SCOT ANALYSIS
10.3.4. CARDINAL HEALTH INC.
10.3.4.1. OVERVIEW
10.3.4.2. PRODUCT PORTFOLIO
10.3.4.3. STRATEGIC INITIATIVES
10.3.4.4. SCOT ANALYSIS
10.3.5. GE HEALTHCARE LIMITED
10.3.5.1. OVERVIEW
10.3.5.2. PRODUCT PORTFOLIO
10.3.5.3. STRATEGIC INITIATIVES
10.3.5.4. SCOT ANALYSIS
10.3.6. AGILENT TECHNOLOGIES INC.
10.3.6.1. OVERVIEW
10.3.6.2. PRODUCT PORTFOLIO
10.3.6.3. STRATEGIC INITIATIVES
10.3.6.4. SCOT ANALYSIS
10.3.7. MASIMO CORPORATION
10.3.7.1. OVERVIEW
10.3.7.2. PRODUCT PORTFOLIO
10.3.7.3. STRATEGIC INITIATIVES
10.3.7.4. SCOT ANALYSIS
10.3.8. NATUS MEDICAL INCORPORATED
10.3.8.1. OVERVIEW
10.3.8.2. PRODUCT PORTFOLIO
10.3.8.3. STRATEGIC INITIATIVES
10.3.8.4. SCOT ANALYSIS
10.3.9. MEDTRONIC PLC
10.3.9.1. OVERVIEW
10.3.9.2. PRODUCT PORTFOLIO
10.3.9.3. STRATEGIC INITIATIVES
10.3.9.4. SCOT ANALYSIS
10.3.10. THERMO FISHER SCIENTIFIC INC.
10.3.10.1. OVERVIEW
10.3.10.2. PRODUCT PORTFOLIO
10.3.10.3. STRATEGIC INITIATIVES
10.3.10.4. SCOT ANALYSIS
10.3.11. NEOGEN LABS PVT. LTD.
10.3.11.1. OVERVIEW
10.3.11.2. PRODUCT PORTFOLIO
10.3.11.3. STRATEGIC INITIATIVES
10.3.11.4. SCOT ANALYSIS
10.3.12. PERKINELMER INC.
10.3.12.1. OVERVIEW
10.3.12.2. PRODUCT PORTFOLIO
10.3.12.3. STRATEGIC INITIATIVES
10.3.12.4. SCOT ANALYSIS
10.3.13. ZENTECH S.A.
10.3.13.1. OVERVIEW
10.3.13.2. PRODUCT PORTFOLIO
10.3.13.3. STRATEGIC INITIATIVES
10.3.13.4. SCOT ANALYSIS
10.3.14. WATERS CORPORATION
10.3.14.1. OVERVIEW
10.3.14.2. PRODUCT PORTFOLIO
10.3.14.3. STRATEGIC INITIATIVES
10.3.14.4. SCOT ANALYSIS
10.3.15. TRIVITRON HEALTHCARE
10.3.15.1. OVERVIEW
10.3.15.2. PRODUCT PORTFOLIO
10.3.15.3. STRATEGIC INITIATIVES
10.3.15.4. SCOT ANALYSIS

List of Tables
TABLE 1. NORTH AMERICA NEWBORN SCREENING MARKET, BY COUNTRY, 2019-2027 (IN $ MILLION)
TABLE 2. NORTH AMERICA INCIDENCE OF CHROMOSOMAL ABNORMALITIES IN NEWBORNS
TABLE 3. LEADING CAUSE OF INFANT DEATH IN THE UNITED STATES
TABLE 4. INFANT MORTALITY RATE IN DEVELOPING COUNTRIES (TOTAL DEATH/ 1000 LIVE BIRTHS)
TABLE 5. NORTH AMERICA NEWBORN SCREENING MARKET, BY PRODUCT, 2019-2027, (IN $ MILLION)
TABLE 6. NORTH AMERICA NEWBORN SCREENING MARKET, BY TEST TYPE, 2019-2027, (IN $ MILLION)
TABLE 7. NORTH AMERICA NEWBORN SCREENING MARKET, BY TECHNOLOGY, 2019-2027, (IN $ MILLION)
TABLE 8. OPPORTUNITY MATRIX
TABLE 9. VENDOR LANDSCAPE
TABLE 10. REGULATORY FRAMEWORK
TABLE 11. NORTH AMERICA NEWBORN SCREENING MARKET, BY COUNTRY, 2019-2027, (IN $ MILLION)
TABLE 12. LIST OF PRODUCT LAUNCHES

List of Figures
FIGURE 1. NORTH AMERICA NEWBORN SCREENING INSTRUMENTS MARKET, BY TECHNOLOGY, 2018 & 2027 (IN %)
FIGURE 2. CAUSES OF DEATH AMONG NEWBORNS NORTH AMERICA (0-27 DAYS)
FIGURE 3. FERTILITY RATE (AVERAGE BIRTHS PER WOMAN IN %) 2017
FIGURE 4. NORTH AMERICA NEWBORN SCREENING MARKET, BY NEWBORN SCREENING INSTRUMENTS, 2019-2027 (IN $ MILLION)
FIGURE 5. NORTH AMERICA NEWBORN SCREENING MARKET, BY NEWBORN SCREENING REAGENTS & ASSAY KITS, 2019-2027 (IN $ MILLION)
FIGURE 6. NORTH AMERICA NEWBORN SCREENING MARKET, BY HEARING SCREEN TEST, 2019-2027 (IN $ MILLION)
FIGURE 7. NORTH AMERICA NEWBORN SCREENING MARKET, BY CRITICAL CONGENITAL HEART DISEASE (CCHD) TEST, 2019-2027 (IN $ MILLION)
FIGURE 8. NORTH AMERICA NEWBORN SCREENING MARKET, BY DRY BLOOD SPOT TEST, 2019-2027 (IN $ MILLION)
FIGURE 9. NORTH AMERICA NEWBORN SCREENING MARKET, BY TANDEM MASS SPECTROMETRY, 2019-2027 (IN $ MILLION)
FIGURE 10. NORTH AMERICA NEWBORN SCREENING MARKET, BY PULSE OXIMETRY, 2019-2027 (IN $ MILLION)
FIGURE 11. NORTH AMERICA NEWBORN SCREENING MARKET, BY ENZYME BASED ASSAYS, 2019-2027 (IN $ MILLION)
FIGURE 12. NORTH AMERICA NEWBORN SCREENING MARKET, BY DNA BASED ASSAYS, 2019-2027 (IN $ MILLION)
FIGURE 13. NORTH AMERICA NEWBORN SCREENING MARKET, BY ELECTROPHORESIS, 2019-2027 (IN $ MILLION)
FIGURE 14. NORTH AMERICA NEWBORN SCREENING MARKET, BY OTHERS, 2019-2027 (IN $ MILLION)
FIGURE 15. PORTER’S FIVE FORCE ANALYSIS
FIGURE 16. KEY BUYING IMPACT ANALYSIS
FIGURE 17. VALUE CHAIN ANALYSIS
FIGURE 18. NORTH AMERICA NEWBORN SCREENING MARKET, REGIONAL OUTLOOK, 2018 & 2027 (IN %)
FIGURE 19. UNITED STATES NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLION)
FIGURE 20. CANADA NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLION)
FIGURE 21. INDUSTRY PLAYER POSITIONING IN 2018 (IN %)
 



List of Figures


FIGURE 1. NORTH AMERICA NEWBORN SCREENING INSTRUMENTS MARKET, BY TECHNOLOGY, 2018 & 2027 (IN %)
FIGURE 2. CAUSES OF DEATH AMONG NEWBORNS NORTH AMERICA (0-27 DAYS)
FIGURE 3. FERTILITY RATE (AVERAGE BIRTHS PER WOMAN IN %) 2017
FIGURE 4. NORTH AMERICA NEWBORN SCREENING MARKET, BY NEWBORN SCREENING INSTRUMENTS, 2019-2027 (IN $ MILLION)
FIGURE 5. NORTH AMERICA NEWBORN SCREENING MARKET, BY NEWBORN SCREENING REAGENTS & ASSAY KITS, 2019-2027 (IN $ MILLION)
FIGURE 6. NORTH AMERICA NEWBORN SCREENING MARKET, BY HEARING SCREEN TEST, 2019-2027 (IN $ MILLION)
FIGURE 7. NORTH AMERICA NEWBORN SCREENING MARKET, BY CRITICAL CONGENITAL HEART DISEASE (CCHD) TEST, 2019-2027 (IN $ MILLION)
FIGURE 8. NORTH AMERICA NEWBORN SCREENING MARKET, BY DRY BLOOD SPOT TEST, 2019-2027 (IN $ MILLION)
FIGURE 9. NORTH AMERICA NEWBORN SCREENING MARKET, BY TANDEM MASS SPECTROMETRY, 2019-2027 (IN $ MILLION)
FIGURE 10. NORTH AMERICA NEWBORN SCREENING MARKET, BY PULSE OXIMETRY, 2019-2027 (IN $ MILLION)
FIGURE 11. NORTH AMERICA NEWBORN SCREENING MARKET, BY ENZYME BASED ASSAYS, 2019-2027 (IN $ MILLION)
FIGURE 12. NORTH AMERICA NEWBORN SCREENING MARKET, BY DNA BASED ASSAYS, 2019-2027 (IN $ MILLION)
FIGURE 13. NORTH AMERICA NEWBORN SCREENING MARKET, BY ELECTROPHORESIS, 2019-2027 (IN $ MILLION)
FIGURE 14. NORTH AMERICA NEWBORN SCREENING MARKET, BY OTHERS, 2019-2027 (IN $ MILLION)
FIGURE 15. PORTER’S FIVE FORCE ANALYSIS
FIGURE 16. KEY BUYING IMPACT ANALYSIS
FIGURE 17. VALUE CHAIN ANALYSIS
FIGURE 18. NORTH AMERICA NEWBORN SCREENING MARKET, REGIONAL OUTLOOK, 2018 & 2027 (IN %)
FIGURE 19. UNITED STATES NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLION)
FIGURE 20. CANADA NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLION)
FIGURE 21. INDUSTRY PLAYER POSITIONING IN 2018 (IN %)

 

List of Tables


TABLE 1. NORTH AMERICA NEWBORN SCREENING MARKET, BY COUNTRY, 2019-2027 (IN $ MILLION)
TABLE 2. NORTH AMERICA INCIDENCE OF CHROMOSOMAL ABNORMALITIES IN NEWBORNS
TABLE 3. LEADING CAUSE OF INFANT DEATH IN THE UNITED STATES
TABLE 4. INFANT MORTALITY RATE IN DEVELOPING COUNTRIES (TOTAL DEATH/ 1000 LIVE BIRTHS)
TABLE 5. NORTH AMERICA NEWBORN SCREENING MARKET, BY PRODUCT, 2019-2027, (IN $ MILLION)
TABLE 6. NORTH AMERICA NEWBORN SCREENING MARKET, BY TEST TYPE, 2019-2027, (IN $ MILLION)
TABLE 7. NORTH AMERICA NEWBORN SCREENING MARKET, BY TECHNOLOGY, 2019-2027, (IN $ MILLION)
TABLE 8. OPPORTUNITY MATRIX
TABLE 9. VENDOR LANDSCAPE
TABLE 10. REGULATORY FRAMEWORK
TABLE 11. NORTH AMERICA NEWBORN SCREENING MARKET, BY COUNTRY, 2019-2027, (IN $ MILLION)
TABLE 12. LIST OF PRODUCT LAUNCHES